SYK launches the T2 Alpha Humerus Nailing System to enhance complex fracture care, boosting procedural efficiency and strengthening its trauma portfolio.
SYK shares rise after fourth-quarter EPS and sales top estimates, fueled by double-digit organic growth and strong adoption of its Mako platform.
Stryker Corporation (SYK) Q4 2025 Earnings Call Transcript
| Health Care Equipment & Supplies Industry | Healthcare Sector | Kevin A. Lobo CEO | XFRA Exchange | US8636671013 ISIN |
| US Country | 53,000 Employees | 30 Apr 2026 Last Dividend | 17 May 2004 Last Split | - IPO Date |
Stryker Corporation is a leading medical technology company with a primary focus on providing innovative solutions in the medical field. The company operates through two main segments: MedSurg and Neurotechnology, and Orthopaedics and Spine. These segments cater to a wide array of medical needs, from total joint replacements and trauma surgeries to advanced neurosurgical and neurovascular solutions. Founded in 1941 and based in Portage, Michigan, Stryker has grown into a global entity, distributing its products in approximately 75 countries. The company's commitment to enhancing patient and caregiver outcomes is evident through its extensive product portfolio, advanced medical devices, and a strategic approach to market distribution and customer engagement.
Stryker Corporation offers a diverse range of products and services designed to cater to various facets of medical care, spanning various specialties and requirements. These include:
These products are made available to doctors, hospitals, and other healthcare facilities through a blend of company-owned subsidiaries and branches, supplemented by a network of third-party dealers and distributors worldwide.